NRXBF (NurExone Biologic) EV-to-EBIT : -7.65 (As of May. 05, 2025)

View and export this data going back to 2023. Start your Free Trial

What is NurExone Biologic EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NurExone Biologic's Enterprise Value is $38.36 Mil. NurExone Biologic's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.02 Mil. Therefore, NurExone Biologic's EV-to-EBIT for today is -7.65.

The historical rank and industry rank for NurExone Biologic's EV-to-EBIT or its related term are showing as below:

NRXBF' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.64 Med: 0 Max: 0
Current: -7.64

NRXBF's EV-to-EBIT is ranked worse than
100% of 470 companies
in the Biotechnology industry
Industry Median: 8.29 vs NRXBF: -7.64

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NurExone Biologic's Enterprise Value for the quarter that ended in Dec. 2024 was $29.89 Mil. NurExone Biologic's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.02 Mil. NurExone Biologic's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -16.78%.

NurExone Biologic EV-to-EBIT Historical Data

The historical data trend for NurExone Biologic's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic EV-to-EBIT Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EV-to-EBIT

-1.21

-2.77

-6.02

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial										-2.77	-8.94	-7.35	-6.44	-6.02

Competitive Comparison of NurExone Biologic's EV-to-EBIT

For the Biotechnology subindustry, NurExone Biologic's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

NurExone Biologic EV-to-EBIT Calculation

NurExone Biologic's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	38.359	/	-5.017
	=	-7.65

NurExone Biologic's current Enterprise Value is $38.36 Mil.
NurExone Biologic's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.02 Mil.

NurExone Biologic (OTCPK:NRXBF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

NurExone Biologic's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 )	=	EBIT	/	Enterprise Value (Q: Dec. 2024 )
	=	-5.017	/	29.89482
	=	-16.78 %

NurExone Biologic's Enterprise Value for the quarter that ended in Dec. 2024 was $29.89 Mil.
NurExone Biologic's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.02 Mil.

NurExone Biologic EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (OTCPK:NRXBF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

J90:Germany NRX:Canada

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.